Akut Koroner Sendromlu Hastalarda Tirofibanın Ortalama Trombosit Hacmine Etkisi

ÖzGiriş: Kardiyovasküler hastalıklar önde gelen ölüm nedenleri olarak bilinmektedir.Tirofiban GPIIb / IIIa reseptör antagonisti olup , trombosit agregasyonunu etkili bir şekilde inhibe eder. Ortalama Trombosit Hacmi trombosit aktivasyonunu gösteren bir markerdir. Çalışmamızda tirofibanın ortalam trombosit hacmine etkisini değerlendirmeği amaçladık.Yöntem: Çalışmaya tedavisine 300 mg aspirin 600 mg klopidogrel verilen grup (n:20)ve bu ikili antiplatelet tedaviye ek olarak tirofiban eklenen grup (n:56) olmak üzereiki gruba ayrıldı. Bu iki gurubun tedavi öncesi ve sonrası hematolojik parametreleri değerlendirildi. Bulgular: İşlem öncesi ve sonrası ortalam trombosit hacmi karşılaştırıldığında ortalama trombosit hacminin tirofiban verilen gurupta istatistiksel olarak anlamlı şekilde düştüğü izlendi. (8,31±1,12; 7,89±0,81 p<0,001).Sonuç:Çalışmamızda yoğun trombüs yükü olan hastalarda tirofibanın kullanılmasının ortalama trombosit hacmi nin azalaması üzerine olumlu etkisi olduğu gösterilmiştir.

The Effect of Tirofiban on Average Platelet Volumein Patients with Acute Coronary Syndrom

AbstractIntroduction: Cardiovascular diseases are known as leading causes of death. The ti-rofiban GPIIb / IIIa receptor antagonist effectively inhibits platelet aggregation. MeanPlatelet Volume is a marker indicating platelet activation. We aimed to evaluate the ef-fect of tirofiban on the mean platelet volume in our study.Methods:The patients were divided into two groups: the control group treat with 300mg aspirin 600 mg clopidogrel (n: 20) and the other group (tirofiban group n: 56) in addition to these two antiplatelet treatments. Hematological parameters of these two groups were evaluated before and after treatment.Results:When the mean platelet volume was compared before and after the procedure, it was observed that the mean platelet volume decreased statistically in the tirofiban group. (8,31 ± 1,12; 7,89 ± 0,81 p <0,001).Conclusion:in our study has been shown that the use of tirofiban in patients withintense thrombus load a positive effect on the reduction of mean platelet volume.

___

  • Kaynaklar 1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk Vet al : ESC/EACTS Guidelines on myocardial revasculariza-tion: The task force on myocardial revascularization of the Eu-ropean Society of Cardiology (ESC) and the European Asso-ciation for Cardio-Thoracic Surgery (EACTS) developed withthe special contribution of the European Association of per-cutaneous cardiovascular interventions (EAPCI). Eur HeartJ 2014; 35, 2541–2619 [PubMed] 2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Ma-caya C, Bass TAet al : Variability in individual responsive-ness to clopidogrel: Clinical implications, management, andfuture perspectives. J Am Coll Cardiol 2007; 49, 1505–1516[PubMed] 3. Aradi D, Tornyos A, Pinter T, Vorobcsuk A, Konyi A, Falu-kozy Jet al : Optimizing P2Y12 receptor inhibition in patientswith acute coronary syndrome on the basis of platelet func-tion testing: Impact of prasugrel and high-dose clopidogrel.J Am Coll Cardiol 2014; 63, 1061–1070 [PubMed] 4. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van ’t Hof AW,Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, DanziGB, Briguori C, et al : Tirofiban as adjunctive therapy for acu-te coronary syndromes and percutaneous coronary interven-tion: A meta-analysis of randomized trials. Eur Heart J 31,35–49 (2010) [PubMed] 5.Park Y, Schoene N, Harris W. Mean platelet volume as an in-dicator of platelet activation: methodological issues. Plate-lets 2002;13(5–6): 301–6 6. Boos CJ, Balakrishnan B, Lip GY. The effects of coronary ar-tery disease severity on time-dependent changes in platelet ac-tivation indices in stored whole blood. J Thromb Thromboly-sis 2008;25(2):135–40 7. Martin JF, Bath PM, Burr ML. Inuence of platelet size on out-come after myocardial infarction. Lancet 1991;338(8780):1409–11. 8. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Kon-kle B, et al. Mean platelet volume as a predictor of cardiovas-cular risk: a systematic review and meta-analysis. J ThrombHaemost 2010;8(1):148–56 9. Bath P, Algert C, Chapman N, Neal B. Association of meanplatelet volume with risk of stroke among 3134 individuals withhistory of cerebrovascular disease. Stroke 2004;35(3):622–6 10.Ten Berg, J. M., van’t Hof, A. W., Dill, T., et al. (2010). Ef-fect of early, pre-hospital initiation of high bolus dose tirofi-ban in patients with ST-segment elevation myocardial infarc-tion on short- and long-term clinical outcome. Journal of theAmerican College of Cardiology, 55, 2446–2455 11. Kupo P , Aradı D , Tornyos A, Füzesı MT, Komocsı A. Assess-ment of platelet function in patients receiving tirofiban earlyafter primary coronary intervention. Interventional Medici-ne & Applied Science, Vol. 2016; 8 : 135–140 12. Karpatkin S. Heterogeneity of human platelets. II. Functio-nal evidence suggestive of young and old platelets. J Clin In-vest 1969;48(6):1083-7. 13. Martin JF, Trowbridge EA, Salmon GL, Plumb J. The biolo-gical significance of platelet volume: its relationship tobleeding time, platelet thromboxane B2 production and me-gakaryocyte nuclear DNA concentration. Thromb Res1983;32(5):443- 60. 14. Van der Loo B, Martin JF. A role for changes in platelet pro-duction in the cause of acute coronary syndromes. Arteriosc-ler Thromb Vasc Biol 1999;19(3):672-9 15.Park Y, Schoene N, Harris W. Mean platelet volume as an in-dicator of platelet activation: methodological issues. Plate-lets 2002;13(5–6): 301–6. 16. Boos CJ, Balakrishnan B, Lip GY. The effects of coronary ar-tery disease severity on time-dependent changes in platelet ac-tivation indices in stored whole blood. J Thromb Thromboly-sis 2008;25(2):135–40. 17. Martin JF, Bath PM, Burr ML. Influence of platelet size onoutcome after myocardial infarction. Lancet 1991;338(8780):1409–11. 18. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Kon-kle B, et al. Mean platelet volume as a predictor of cardiovas-cular risk: a systematic review and meta-analysis. J ThrombHaemost 2010;8(1):148–56. 19. Bath P, Algert C, Chapman N, Neal B. Association of meanplatelet volume with risk of stroke among 3134 individuals withhistory of cerebrovascular disease. Stroke 2004;35622–6. 20. Icli A, Aksoy F, Turker Y, Uysal B A, Alpay M F, Dogan Aetal : Relationship Between Mean Platelet Volume and Pulmo-nary Embolism in Patients With Deep Vein Thrombosis. He-art, Lung and Circulation 2015 xx, 1–6 21. Behan MW, Storey RF. Antiplatelet therapy in cardiovascu-lar disease. Postgrad Med J 2004;80:155-164